Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC74599 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 10632 |
0.1-0.2 | 17397 |
0.2-0.3 | 2138 |
0.3-0.4 | 546 |
0.4-0.5 | 138 |
0.5-0.6 | 16 |
0.6-0.7 | 12 |
0.7-0.8 | 7 |
0.8-0.85 | 1 |
0.85-0.9 | 2 |
0.9-0.95 | 0 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC74599 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 521 |
0.1-0.2 | 6206 |
0.2-0.3 | 1911 |
0.3-0.4 | 390 |
0.4-0.5 | 79 |
0.5-0.6 | 32 |
0.6-0.7 | 17 |
0.7-0.8 | 1 |
0.8-0.85 | 3 |
0.85-0.9 | 0 |
0.9-0.95 | 1 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9429 |
High Similarity |
NPD2707 |
Clinical (unspecified phase) |
0.8485 |
Intermediate Similarity |
NPD401 |
Approved |
0.8235 |
Intermediate Similarity |
NPD1156 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD2276 |
Clinical (unspecified phase) |
0.7073 |
Intermediate Similarity |
NPD2273 |
Clinical (unspecified phase) |
0.6857 |
Remote Similarity |
NPD9465 |
Approved |
0.6757 |
Remote Similarity |
NPD5384 |
Approved |
0.6757 |
Remote Similarity |
NPD2274 |
Approved |
0.6757 |
Remote Similarity |
NPD5385 |
Approved |
0.6757 |
Remote Similarity |
NPD2275 |
Approved |
0.6744 |
Remote Similarity |
NPD9458 |
Approved |
0.6667 |
Remote Similarity |
NPD1463 |
Clinical (unspecified phase) |
0.6596 |
Remote Similarity |
NPD395 |
Approved |
0.6596 |
Remote Similarity |
NPD396 |
Approved |
0.6571 |
Remote Similarity |
NPD9063 |
Approved |
0.6571 |
Remote Similarity |
NPD9064 |
Approved |
0.6486 |
Remote Similarity |
NPD2706 |
Approved |
0.6486 |
Remote Similarity |
NPD2705 |
Approved |
0.6486 |
Remote Similarity |
NPD3734 |
Approved |
0.6364 |
Remote Similarity |
NPD390 |
Approved |
0.6364 |
Remote Similarity |
NPD718 |
Approved |
0.6136 |
Remote Similarity |
NPD9227 |
Discontinued |
0.5882 |
Remote Similarity |
NPD3721 |
Approved |
0.5882 |
Remote Similarity |
NPD3722 |
Approved |
0.5854 |
Remote Similarity |
NPD1832 |
Approved |
0.5854 |
Remote Similarity |
NPD1833 |
Approved |
0.5833 |
Remote Similarity |
NPD9459 |
Approved |
0.5833 |
Remote Similarity |
NPD9460 |
Approved |
0.5769 |
Remote Similarity |
NPD4839 |
Approved |
0.5758 |
Remote Similarity |
NPD8560 |
Clinical (unspecified phase) |
0.5676 |
Remote Similarity |
NPD9013 |
Clinical (unspecified phase) |
0.5676 |
Remote Similarity |
NPD9012 |
Phase 2 |
0.5641 |
Remote Similarity |
NPD9039 |
Approved |
0.5641 |
Remote Similarity |
NPD9041 |
Approved |
0.5641 |
Remote Similarity |
NPD9040 |
Clinical (unspecified phase) |
0.5625
|
Remote Similarity |
NPD1154 |
Phase 3 |